Highlights Sol-Gel Technologies Ltd. Börse Stuttgart

Equities

4SG

IL0011417206

Delayed Börse Stuttgart Other stock markets 01:03:11 03/07/2024 pm IST			5-day change	1st Jan Change
0.785 ^EUR	+1.95%		+8.45%	-28.70%

28/05	Sol-Gel Technologies Gets Noncompliance Notice From Nasdaq	MT
28/05	Sol-Gel Technologies Ltd. Announces Resignation of Gilad Mamlok as Chief Financial Officer, Effective September 21, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sol-Gel Technologies Gets Noncompliance Notice From Nasdaq	28/05	MT
Sol-Gel Technologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	20/05	CI
Sol-Gel Technologies Ltd. and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize Twyneo® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel	16/05	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03	CI
Sol-Gel Technologies Ltd. Screens First Patient for SGT-610 Phase 3 Study	30/11	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Sol-Gel Technologies, Searchlight Pharma Sign Licensing Deals for 2 Dermatology Drugs	06/23/06	MT
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO and EPSOLAY in Canada	06/23/06	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	10/23/10	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	10/23/10	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22/22/22	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	04/22/04	CI
Sol-Gel Technologies Announces FDA Approval of EPSOLAY	25/22/25	CI
Sol-Gel Grants Galderma Holding SA the Exclusive Rights to Commercialize EPSOLAY in the United States	25/22/25	CI
Sol-Gel Technologies Announces the Commercial Availability of TWYNEO	14/22/14	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	30/22/30	CI
Sol-Gel Technologies Says US FDA to Inspect its Epsolay Production Site in February	21/21/21	MT
Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®	21/21/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sol-Gel Technologies Ltd. Börse Stuttgart

Equities

4SG

IL0011417206

Highlights

Filters